Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress and Continuing Medical Education: Last Chance for Self-Policing

This article was originally published in RPM Report

Executive Summary

Senate Finance Committee minority staff investigator Paul Thacker has been a leading figure behind the effort to make public the recipients of pharma funding and grants. Here are his thoughts from a recent conference on the future of industry funded CME.

You may also be interested in...

Let The Sunshine In: Health Care Reform Law Mandates Public Disclosure of Financial Ties Between Industry and Physicians

The "physician payments sunshine" provisions of the recently enacted health care reform legislation may chill relations between industry and physicians. They also are likely to impose significant costs on drug and device manufacturers.

Conflicts of Interest: More Questions than Answers

It was fitting that this year's TCT conference included a session on physician/industry conflicts of interest since this has been a hot topic recently in the press, and because TCT is probably the most industry-focused of all the major clinical conferences. Not surprisingly, the panel of physicians raised more questions than answers about both individual and institutional conflicts and how they should be handled.

Medicaid Fraud Scorecard

Pharma's $2 billion in payouts since 2000 to settle claims of fraudulent Medicaid-related marketing and pricing practices has left the industry in flux, as it seeks to determine the kinds of packages and programs that will pass government muster. It appears that the strength of many current and presumed future fraud cases will be based on establishing a company's reasonable foreknowledge of the activities of its customers, with the argument even extended to gray areas including improper encouragement of off-label drug usage and the development of data to support those uses--issues that will affect device companies at least as much as Pharma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts